Volume 122, Issue 6 , Pages 1200-1207.e1, December 2008
Resistin-like molecule α enhances myeloid cell activation and promotes colitis
Background
Resistin-like molecule (Relm) α is a secreted protein and a hallmark signature gene for alternatively activated macrophages. Relm-α is highly induced by allergic inflammatory triggers and perceived to promote tissue repair. Yet the function of Relm-α remains unknown.
Objective
We sough to determine the role of Relm-α in dextran sodium sulfate (DSS)–induced colonic injury.
Methods
The cellular source of Relm-α was determined after oral DSS-induced colitis. Retnla−/− mice were generated, subjected to DSS treatment, and monitored for disease progression (clinical and histopathologic features). Cytokine production in the supernatants of ex vivo colon cultures, and of LPS-stimulated macrophages incubated with Relm-α was assessed. Relm-α was administered intraperitoneally, and the cellular recruitment to the peritoneum was assessed.
Results
After innate intestinal stimulation with DSS, Relm-α was highly expressed by eosinophils and epithelial cells. Retnla gene–targeted mice were protected from DSS-induced colitis (eg, decreased diarrhea, rectal bleeding, colon shortening, disease score, and histopathologic changes). Relm-α coactivated IL-6 and TNF-α release and inhibited IL-10 release from LPS-activated bone marrow–derived macrophages. Consistent with these finding, colon cultures of DSS-treated Retnla−/− mice produced decreased IL-6 and increased IL-10 ex vivo. Furthermore, Retnla−/− mice had substantially decreased c-Jun N-terminal kinase phosphorylation in vivo. In vivo administration of Relm-α initiated cellular recruitment to the peritoneum, and Relm-α was able to induce eosinophil chemotaxis in vitro.
Conclusions
These findings demonstrate a central proinflammatory role for Relm-α in colonic innate immune responses, identifying a novel pathway for regulation of macrophage activation.
Key words: Resistin-like molecule α, colitis, macrophages, eosinophils, LPS, inflammation, inflammatory bowel disease
Abbreviations used: DAPI, 4′,6-Diamidino-2-phenylindole dihydrochloride, DSS, Dextran sodium sulfate, IBD, Inflammatory bowel disease, MBP, Major basic protein, pJNK, Phospho–c-Jun N-terminal kinase, Relm, Resistin-like molecule
Supported by National Institutes of Health grants P01 HL-076383 (M.E.R.) and R01 AI057803 (M.E.R.), a fellowship award (A.M) from the Machiah Foundation, a supporting foundation of the Jewish Community Endowment Fund, the generous support of the Alexander M. and June L. Maisin Foundation, and the Kanbar Charitable Trust, the Campaign Urging Research for Eosinophilic Disorders (CURED), the Food Allergy Project, and the Buckeye Foundation.
Disclosure of potential conflict of interest: M. E. Rothenberg is on the speakers' bureau for Merck; has consulting arrangements with Merck, Ception Therapeutics, Novartis, and Nycomed; and has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)01864-2
doi:10.1016/j.jaci.2008.10.017
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 122, Issue 6 , Pages 1200-1207.e1, December 2008
